Hematological Malignancy Drugs Market, Global Outlook and Forecast 2022-2028

Hematological Malignancy Drugs Market, Global Outlook and Forecast 2022-2028

Report Code: KNJ1318501 | No. of Pages: 104 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: May-2022
This report contains market size and forecasts of Hematological Malignancy Drugs in Global, including the following market information:
Global Hematological Malignancy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hematological Malignancy Drugs market was valued at  million in 2021 and is projected to reach US$  million by 2028, at a CAGR of  % during the forecast period 2022-2028.
The U.S. Market is Estimated at $  Million in 2021, While China is Forecast to Reach $  Million by 2028.
Monoclonal Antibody Segment to Reach $  Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hematological Malignancy Drugs include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hematological Malignancy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematological Malignancy Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hematological Malignancy Drugs Market Segment Percentages, by Type, 2021 (%)
    Monoclonal Antibody
    Immunomodulatory Drug
    Tyrosine Kinase Inhibitor
    Proteasome Inhibitors
    Others
Global Hematological Malignancy Drugs Market, by Indication, 2017-2022, 2023-2028 ($ millions)
Global Hematological Malignancy Drugs Market Segment Percentages, by Indication, 2021 (%)
    ALL
    CLL
    AML
    NHL
    DLBCL
    MM
    Others
Global Hematological Malignancy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hematological Malignancy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematological Malignancy Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hematological Malignancy Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Roche
    Celgene
    Novartis
    Bristol-Myers Squibb
    Johnson & Johnson
    Merck & Co.
    AstraZeneca
    Pfizer
    Amgen
    Eli Lilly
    AbbVie
    Takeda
    Sanofi
    Bayer
    Biogen Idec
1 Introduction to Research & Analysis Reports
    1.1 Hematological Malignancy Drugs Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Indication
    1.3 Global Hematological Malignancy Drugs Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Hematological Malignancy Drugs Overall Market Size
    2.1 Global Hematological Malignancy Drugs Market Size: 2021 VS 2028
    2.2 Global Hematological Malignancy Drugs Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Hematological Malignancy Drugs Players in Global Market
    3.2 Top Global Hematological Malignancy Drugs Companies Ranked by Revenue
    3.3 Global Hematological Malignancy Drugs Revenue by Companies
    3.4 Top 3 and Top 5 Hematological Malignancy Drugs Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Hematological Malignancy Drugs Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Hematological Malignancy Drugs Players in Global Market
        3.6.1 List of Global Tier 1 Hematological Malignancy Drugs Companies
        3.6.2 List of Global Tier 2 and Tier 3 Hematological Malignancy Drugs Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Hematological Malignancy Drugs Market Size Markets, 2021 & 2028
        4.1.2 Monoclonal Antibody
        4.1.3 Immunomodulatory Drug
        4.1.4 Tyrosine Kinase Inhibitor
        4.1.5 Proteasome Inhibitors
        4.1.6 Others
    4.2 By Type - Global Hematological Malignancy Drugs Revenue & Forecasts
        4.2.1 By Type - Global Hematological Malignancy Drugs Revenue, 2017-2022
        4.2.2 By Type - Global Hematological Malignancy Drugs Revenue, 2023-2028
        4.2.3 By Type - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Hematological Malignancy Drugs Market Size, 2021 & 2028
        5.1.2 ALL
        5.1.3 CLL
        5.1.4 AML
        5.1.5 NHL
        5.1.6 DLBCL
        5.1.7 MM
        5.1.8 Others
    5.2 By Indication - Global Hematological Malignancy Drugs Revenue & Forecasts
        5.2.1 By Indication - Global Hematological Malignancy Drugs Revenue, 2017-2022
        5.2.2 By Indication - Global Hematological Malignancy Drugs Revenue, 2023-2028
        5.2.3 By Indication - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Hematological Malignancy Drugs Market Size, 2021 & 2028
    6.2 By Region - Global Hematological Malignancy Drugs Revenue & Forecasts
        6.2.1 By Region - Global Hematological Malignancy Drugs Revenue, 2017-2022
        6.2.2 By Region - Global Hematological Malignancy Drugs Revenue, 2023-2028
        6.2.3 By Region - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Hematological Malignancy Drugs Revenue, 2017-2028
        6.3.2 US Hematological Malignancy Drugs Market Size, 2017-2028
        6.3.3 Canada Hematological Malignancy Drugs Market Size, 2017-2028
        6.3.4 Mexico Hematological Malignancy Drugs Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Hematological Malignancy Drugs Revenue, 2017-2028
        6.4.2 Germany Hematological Malignancy Drugs Market Size, 2017-2028
        6.4.3 France Hematological Malignancy Drugs Market Size, 2017-2028
        6.4.4 U.K. Hematological Malignancy Drugs Market Size, 2017-2028
        6.4.5 Italy Hematological Malignancy Drugs Market Size, 2017-2028
        6.4.6 Russia Hematological Malignancy Drugs Market Size, 2017-2028
        6.4.7 Nordic Countries Hematological Malignancy Drugs Market Size, 2017-2028
        6.4.8 Benelux Hematological Malignancy Drugs Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Hematological Malignancy Drugs Revenue, 2017-2028
        6.5.2 China Hematological Malignancy Drugs Market Size, 2017-2028
        6.5.3 Japan Hematological Malignancy Drugs Market Size, 2017-2028
        6.5.4 South Korea Hematological Malignancy Drugs Market Size, 2017-2028
        6.5.5 Southeast Asia Hematological Malignancy Drugs Market Size, 2017-2028
        6.5.6 India Hematological Malignancy Drugs Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Hematological Malignancy Drugs Revenue, 2017-2028
        6.6.2 Brazil Hematological Malignancy Drugs Market Size, 2017-2028
        6.6.3 Argentina Hematological Malignancy Drugs Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Hematological Malignancy Drugs Revenue, 2017-2028
        6.7.2 Turkey Hematological Malignancy Drugs Market Size, 2017-2028
        6.7.3 Israel Hematological Malignancy Drugs Market Size, 2017-2028
        6.7.4 Saudi Arabia Hematological Malignancy Drugs Market Size, 2017-2028
        6.7.5 UAE Hematological Malignancy Drugs Market Size, 2017-2028
7 Players Profiles
    7.1 Roche
        7.1.1 Roche Corporate Summary
        7.1.2 Roche Business Overview
        7.1.3 Roche Hematological Malignancy Drugs Major Product Offerings
        7.1.4 Roche Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.1.5 Roche Key News
    7.2 Celgene
        7.2.1 Celgene Corporate Summary
        7.2.2 Celgene Business Overview
        7.2.3 Celgene Hematological Malignancy Drugs Major Product Offerings
        7.2.4 Celgene Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.2.5 Celgene Key News
    7.3 Novartis
        7.3.1 Novartis Corporate Summary
        7.3.2 Novartis Business Overview
        7.3.3 Novartis Hematological Malignancy Drugs Major Product Offerings
        7.3.4 Novartis Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.3.5 Novartis Key News
    7.4 Bristol-Myers Squibb
        7.4.1 Bristol-Myers Squibb Corporate Summary
        7.4.2 Bristol-Myers Squibb Business Overview
        7.4.3 Bristol-Myers Squibb Hematological Malignancy Drugs Major Product Offerings
        7.4.4 Bristol-Myers Squibb Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.4.5 Bristol-Myers Squibb Key News
    7.5 Johnson & Johnson
        7.5.1 Johnson & Johnson Corporate Summary
        7.5.2 Johnson & Johnson Business Overview
        7.5.3 Johnson & Johnson Hematological Malignancy Drugs Major Product Offerings
        7.5.4 Johnson & Johnson Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.5.5 Johnson & Johnson Key News
    7.6 Merck & Co.
        7.6.1 Merck & Co. Corporate Summary
        7.6.2 Merck & Co. Business Overview
        7.6.3 Merck & Co. Hematological Malignancy Drugs Major Product Offerings
        7.6.4 Merck & Co. Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.6.5 Merck & Co. Key News
    7.7 AstraZeneca
        7.7.1 AstraZeneca Corporate Summary
        7.7.2 AstraZeneca Business Overview
        7.7.3 AstraZeneca Hematological Malignancy Drugs Major Product Offerings
        7.7.4 AstraZeneca Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.7.5 AstraZeneca Key News
    7.8 Pfizer
        7.8.1 Pfizer Corporate Summary
        7.8.2 Pfizer Business Overview
        7.8.3 Pfizer Hematological Malignancy Drugs Major Product Offerings
        7.8.4 Pfizer Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.8.5 Pfizer Key News
    7.9 Amgen
        7.9.1 Amgen Corporate Summary
        7.9.2 Amgen Business Overview
        7.9.3 Amgen Hematological Malignancy Drugs Major Product Offerings
        7.9.4 Amgen Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.9.5 Amgen Key News
    7.10 Eli Lilly
        7.10.1 Eli Lilly Corporate Summary
        7.10.2 Eli Lilly Business Overview
        7.10.3 Eli Lilly Hematological Malignancy Drugs Major Product Offerings
        7.10.4 Eli Lilly Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.10.5 Eli Lilly Key News
    7.11 AbbVie
        7.11.1 AbbVie Corporate Summary
        7.11.2 AbbVie Business Overview
        7.11.3 AbbVie Hematological Malignancy Drugs Major Product Offerings
        7.11.4 AbbVie Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.11.5 AbbVie Key News
    7.12 Takeda
        7.12.1 Takeda Corporate Summary
        7.12.2 Takeda Business Overview
        7.12.3 Takeda Hematological Malignancy Drugs Major Product Offerings
        7.12.4 Takeda Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.12.5 Takeda Key News
    7.13 Sanofi
        7.13.1 Sanofi Corporate Summary
        7.13.2 Sanofi Business Overview
        7.13.3 Sanofi Hematological Malignancy Drugs Major Product Offerings
        7.13.4 Sanofi Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.13.5 Sanofi Key News
    7.14 Bayer
        7.14.1 Bayer Corporate Summary
        7.14.2 Bayer Business Overview
        7.14.3 Bayer Hematological Malignancy Drugs Major Product Offerings
        7.14.4 Bayer Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.14.5 Bayer Key News
    7.15 Biogen Idec
        7.15.1 Biogen Idec Corporate Summary
        7.15.2 Biogen Idec Business Overview
        7.15.3 Biogen Idec Hematological Malignancy Drugs Major Product Offerings
        7.15.4 Biogen Idec Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
        7.15.5 Biogen Idec Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com